Peritoneal Dialysis Market is Estimated to Reach $5.58 Billion by 2027

December 23, 2020

Peritoneal Dialysis Market is estimated to reach USD 5.58 Billion by 2027. This can be mainly associated with the growing incidences of chronic diseases and technological advancements that are expected to become the most common growth factors globally in the coming years.

Peritoneal dialysis (PD) is a method of dialysis that uses dialysis solution and the inner lining of the abdomen to drain blood when the kidneys are not functioning efficiently. This method is mostly performed at home and principally works to remove excess waste products and fluid from the blood. ESRD (End-stage renal disease), which is generally known as kidney failure, is a significant factor for the growth of the market.

Diabetes is the most common cause of ESRD, whereas high blood pressure is the second most common cause of ESRD. High blood pressure and diabetes are the most common chronic disease among the global population, and a shortage of kidneys for transplantation due to stringent regulations regarding kidney transplantation in several countries are some of the factors that are responsible for stimulating the market growth.

However, the lack of awareness and limited demand in underdeveloped countries are some factors that may hinder the market growth. The rise in demand for home peritoneal dialysis treatment and increased opportunities in weak and emerging markets would create future opportunities.

Due to the presence of key players, favorable reimbursement policies, and a rising number of chronic diseases, and several initiatives by the government, North America accounts for the largest share of around 35.3% of the market by 2019.

Further key findings from the report suggest

  • Peritoneal dialysis is the cleansing of blood and the elimination of extra fluids by using the peritoneal membrane, the body’s natural filter.
  • Hemodialysis is a method of pumping out the blood to an artificial kidney system and is returned to the body with the help of tubing accessories.
  • The peritoneal membrane is the lining that circles the abdominal cavity, including the stomach, spleen, liver, and intestines.
  • CAPD type segment is expected to grow at a rate of 5.4% during the forecast period due to portability, low cost, and freedom from machines.
  • The growing population, increasing rates of chronic diseases, and rising healthcare expenditure are the fundamental factors that are boosting the growth of the market across the globe.
  • A growing aging population that needs long term care requirements, raising awareness about hospital-acquired infections, and growing usage of technologies among patients are few factors that are expected to expand usage rates.
  • The hospital-based dialysis segment accounts for a market share of approximately 31.2% by 2019.
  • Innovative product development and collaborative developments are some critical strategic initiatives taken by the players in this industry to fortify their position in the competition.
  • The presence of unique diagnostic and therapeutic medical technologies that enable quick and accurate diagnosis is the primary factor for the growth of this segment.
  • The benefits of peritoneal dialysis involve no use of needles, minimum clinic visits, and continuous therapy supplies similar to the kidney’s natural functioning.
  • The peritoneal dialysis solution segment accounted for the largest share of nearly 23.3% by 2019.
  • Europe accounted for a share of about 26.3% in 2019 and is expected to grow at a rate of 5.3% during the forecast period.
  • Key participants include Nipro, Covidien, B. Braun Melsungen, Diversified Specialty Institute Holdings, DaVita Healthcare Partners, Baxter International, Dialysis Clinic, Medical Components, Northwest Kidney Centers, Fresenius Medical Care, Huaren Pharmaceutical, NephroPlus, Satellite Healthcare, NxStage Medical, Renal Services, Sandor, Sichuan Kelun Pharmaceutical, and U.S. Renal Care.


Key Topics Covered:

Chapter 1. Market Synopsis

Chapter 2. Executive Summary

Chapter 3. Indicative Metrics

Chapter 4. Peritoneal Dialysis Market Segmentation & Impact Analysis

Chapter 5. Peritoneal Dialysis Market By Type Insights & Trends

Chapter 6. Peritoneal Dialysis Market By End-User Insights & Trends

Chapter 7. Peritoneal Dialysis Market By Product Insights & Trends

Chapter 8. Peritoneal Dialysis Market Regional Outlook

Chapter 9. Competitive Landscape

Chapter 10. Company Profiles

  • Baxter International
  • Nipro
  • B. Braun Melsungen
  • DaVita Healthcare Partners Co.idien
  • Dialysis Clinic
  • Fresenius Medical Care
  • Diversified Specialty Institute Holdings
  • Medical Components
  • Huaren Pharmaceutical
  • NephroPlus
  • Northwest Kidney Centers
  • Satellite Healthcare
  • NxStage Medical
  • Renal Services
  • Sandor
  • Sichuan Kelun Pharmaceutical
  • U.S. Renal Care

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”